Sunday March 18, 2018
Home India Remembering Y...

Remembering Y Subbarao on his birthday


New Delhi: Today is the 121st birth anniversary of one of finest Indian scientists Yellapragada Subbarao. He is best known for the development of methotrexate for treatment of cancer and also for the discovery of the function of adenosine triphosphate as an energy source.

Born today in a Tamil family in the year 1895, Subbarao completed his graduation from the Presidency college in Madras. He came from a financially crippled background.

A believer and the supporter of Indian freedom struggle, Subbarao was greatly inspired by Gandhi.

After completing his education, he started his research in the area of Ayurveda.

In the 1920s, Subbarao got an opportunity to study in the Harvard University in America where he completed his PhD and began his career as an Assistant faculty member. This was the same period when he made his first crucial breakthrough by developing a method to figure out the estimate of phosphorus in body fluids and tissues with Cyrus Fiske.

He had an important role in the some of the medical research happened in America during the world war II.

He discovered the folic acid and isolated Adenosine Triphosphate.

He got the maximum recognition when a fungus genus was named after him, called Subbaromyces.

At the age of 53, in 1948 Subbarao died in the USA but till then he had made some useful important impact in the field of biochemistry.

In the twenty-first century when India is putting a focus on the schemes like Make In India, it is important that role of such people is remembered so that the country can produce more talents like him. India needs geniuses like Subbarao who can help the nation achieve the development that it is striving for.(image-wikipedia)

Click here for reuse options!
Copyright 2016 NewsGram

Next Story

Pentavalent vaccine: Doctors raise red flag

In spite of the data presented in this paper from a large cohort, the authors point out that the evidence is merely circumstantial and not conclusive

the new Hepatitis B vaccine for adults is called Heplisav-B.
India's PV to be reexamined because of its harmful effects. .
  • Pentavalent vaccine was introduced in India six years ago
  • It is since then have been a cause of many deaths
  • Doctors want it to be reexamined before continuing its use

Pentavalent vaccine (PV), that was introduced by India a little over six years ago, doubled the deaths of children soon after vaccination compared to the DPT (Diphtheria-Pertussis-Tetanus) vaccine, according to a new study that calls for a “rigorous review of the deaths following vaccination with PV”.

Health officials have launched a campaign targeting nearly 24 million people with a one-fifth dose of the vaccine. Wikimedia Commons
PV has been cause of many deaths in past years. Wikimedia Commons

Government records show that there were 10,612 deaths following vaccination (both PV and DPT) in the last 10 years. There was a huge increase in these numbers in 2017, which the Health Ministry has promised to study. “The present analysis could be a starting point in the quest to reduce the numbers of such deaths,” authors of the new study say.

The study by Dr Jacob Puliyel, Head of Pediatrics at St Stephens Hospital, and Dr V. Sreenivas, Professor of Biostatistics at the All-India Institute of Medical Sciences (AIIMS), both in New Delhi, is published in the peer-reviewed Medical Journal of Dr D.Y. Patil University.

PV is a combination of the DPT vaccine and two more vaccines against Haemophilus influenza type B (Hib) and hepatitis B. Starting December 2011, PV was introduced into India’s immunisation programme to replace DPT vaccine in a staged manner with a view to adding protection against Hib and Hepatitis B without increasing the number of injections given to infants.

Doctors have raised concerns over these vaccines. Wikimedia Commons
Doctors have raised concerns over these vaccines. Wikimedia Commons

But sporadic reports of unexplained deaths following immunisation with PV had been a matter of concern. Puliyel, Sreenivas and their colleagues undertook the study to find out if these deaths were merely coincidental or vaccine-induced.

The authors obtained data of all deaths reported from April 2012 to May 2016 under the Right to Information Act. Data on deaths within 72 hours of administering DPT and PV from different states were used.

For their study, the authors assumed that all deaths within 72 hours of receiving DPT are natural deaths. Using this figure as the baseline, they presumed that any increase in the number of deaths above this baseline among children receiving PV must be caused by this vaccine.

Also Read: With Medicine Running Out, Venezuelans With Transplant Live in Fear

According to their analysis of the data provided by the government, there were 237 deaths within 72 hours of administering the Pentavalent vaccine — twice the death rate among infants who received DPT vaccine.

Extrapolating the data, the authors have estimated that vaccination of 26 million children each year in India would result in 122 additional deaths within 72 hours, due to the switch from DPT to PV.

“There is likely to be 7,020 to 8,190 deaths from PV each year if data from states with the better reporting, namely Manipur and Chandigarh, are projected nationwide,” their report says.

It is important to make sure that these vaccines are reexamined peroperly. VOA

The authors note that while the study looks at the short-term increase in deaths (within three days of vaccination) it does not calculate the potential benefits of PV on infant mortality, for example by protection against lethal diseases like Haemophilus influenza.

In spite of the data presented in this paper from a large cohort, the authors point out that the evidence is merely circumstantial and not conclusive. “These findings of differential death rates between DPT and PV do call for further rigorous prospective population-based investigations,” the study concludes. IANS